Cited by 1,509Acute Myocardial Infarction ResearchCardiac Health and Mental HealthCardiac Ischemia and Reperfusion

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

beta Blockade after myocardial infarction: systematic review and meta regression analysis

Open access

Freemantle, N., Cleland, J., Young, P., Mason, J., Harrison, J.·1999·BMJ

DOI 10.1136/bmj.318.7200.1730PMC PMC31101

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVES: To assess the effectiveness of beta blockers in short term treatment for acute myocardial infarction and in longer term secondary prevention; to examine predictive factors that may influence outcome and therefore choice of drug; and to examine the clinical importance of the results in the light of current treatment. DESIGN: Systematic review of randomised controlled trials. SETTING: Randomised controlled trials. SUBJECTS: Patients with acute or past myocardial infarction. INTERVENTION: beta Blockers compared with control. MAIN OUTCOME MEASURES: All cause mortality and non-fatal reinfarction. RESULTS: Overall, 5477 of 54 234 patients (10.1%) randomised to beta blockers or control died. We identified a 23% reduction in the odds of death in long term trials (95% confidence interval 15% to 31%), but only a 4% reduction in the odds of death in short term trials (-8% to 15%). Meta regression in long term trials did not identify a significant reduction in effectiveness in drugs with cardioselectivity but did identify a near significant trend towards decreased benefit in drugs with intrinsic sympathomimetic activity. Most evidence is available for propranolol, timolol, and metoprolol. In long term trials, the number needed to treat for 2 years to avoid a death is 42, which compares favourably with other treatments for patients with acute or past myocardial infarction. CONCLUSIONS: beta Blockers are effective in long term secondary prevention after myocardial infarction, but they are underused in such cases and lead to avoidable mortality and morbidity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.318.7200.1730

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Untitled work
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Sleight, R. B., Sleight, P., Parish, S., Appleby, P. N., Collins, R., & Baigent, C. (1988) · PubMed · Cited by 2,868
Comparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction
The TIMI Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198903093201002 · Cited by 1,024
Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction
Gottlieb, S. S., McCarter, R., & Vogel, R. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390801 · Cited by 966
The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
The Multicenter Diltiazem Postinfarction Trial Research Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190701 · Cited by 828
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
(1994) · Europe PMC (PubMed Central) · Cited by 755
The Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction
Smith, P., Arnesen, H., & Holme, I. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007193230302 · Cited by 637

Show all 34 references

Research works printed but not linked: 3

Viskin S, Barron HV. -Blockers prevent cardiac death following myocar- dial infarction: so why are so many infarct survivors discharge without -blockers? Am J Cardiol 1996;78:821-2.
Spiegelhalter D, Thomas A, Best N, Gilks W. BUGS: Bayesian inference using Gibbs sampling, Version 0.50. Cambridge: Medical Research Council Biostatistics Unit, 1995.
Feely J, de Vane PJ, Maclean D. -Blockers and sympathomimetics. BMJ 1983;286:1043-7.

Sorted by citations

Items 501–600 of 1,000

<![CDATA[Diretrizes de doen�a coronariana cr�nica angina est�vel]]>
C�sar, L. A. M., Mansur, A. D. P., Armaganijan, D., Amino, J. G. D. C., de Sousa, A. S., Sim�o, A. F., Brito, A. X., Caramelli, B., Vianna, C. B., Pastore, C. A., et al. (2004) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2004002100001 · Cited by 27
Heartwatch: a secondary prevention programme in primary care in Ireland
Bennett, K., Jennings, S., Collins, C., Boland, M., Leahy, J., Bedford, D., & Shelley, E. (2008) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283090020 · Cited by 25
Adherence to Beta-Blockers and Long-Term Risk of Heart Failure and Mortality After a Myocardial Infarction
Desta, L., Khedri, M., Jernberg, T., Andell, P., Mohammad, M. A., Hofman‐Bang, C., Erlinge, D., Spaak, J., & Persson, H. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13079 · Cited by 26
Relationships Among Heart Rate, β-Blocker Dosage, and Prognosis in Patients With Coronary Artery Disease in a Real-World Database Using a Multimodal Data Acquisition System
Oba, Y., Kabutoya, T., Kohro, T., Imai, Y., Kario, K., Sato, H., Nochioka, K., Nakayama, M., Fujita, H., Mizuno, Y., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0314 · Cited by 26
The association between study characteristics and outcome in the relation between job stress and cardiovascular disease – a multilevel meta-regression analysis
Szerencsi, K., van Amelsvoort, L. G. P. M., Viechtbauer, W., Mohren, D. C. L., Prins, M. H., & Kant, I. (2012) · Scandinavian Journal of Work Environment & Health · doi:10.5271/sjweh.3283 · Cited by 26
Benefit of Immediate Beta-Blocker Therapy on Mortality in Patients With ST-Segment Elevation Myocardial Infarction*
Hirschl, M. M., Wollmann, C. G., Erhart, F., Brunner, W., Pfeffel, F., Gattermeier, M., Steger, F., & Mayr, H. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827caa64 · Cited by 25
Long-term effect of β-blocker in ST-segment elevation myocardial infarction in patients with preserved left ventricular systolic function: a propensity analysis
Konishi, H., Miyauchi, K., Kasai, T., Tsuboi, S., Ogita, M., Naito, R., Nishizaki, Y., Okai, I., Tamura, H., Okazaki, S., et al. (2015) · Heart and Vessels · doi:10.1007/s00380-014-0624-2 · Cited by 25
“A meta-analysis of 82 randomized trials provides strong evidence for a long-term use of β-blocker to reduce morbidity and mortality after MI [19].”
Background
Improving Care After Myocardial Infarction Using a 2-Year Internet-Delivered Intervention
Levine, D. A. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.498 · Cited by 25
Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction
Makam, R. C. P., Erskine, N. A. K., McManus, D. D., Lessard, D., Gore, J. M., Yarzebski, J., & Goldberg, R. J. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.065 · Cited by 25
Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials
Mengesha, H. G., Sahle, B. W., Petrucka, P. M., Tafesse, T. B., Otieno, M. G., & Hailu, A. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0540-3 · Cited by 26
Drug utilization patterns among elderly hospitalized patients on poly-pharmacy in Punjab, Pakistan
Sarwar, M. R., Atif, M., Scahill, S. L., Saqib, A., Qamar-uz-Zaman, M., & Babar, Z. (2017) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-017-0112-z · Cited by 30
Meta-Epidemiology
Bae, J. (2014) · Epidemiology and Health · doi:10.4178/epih/e2014019 · Cited by 25
Effects of carvedilol early after myocardial infarction: Analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN)
Fonarow, G. C., Lukas, M. A., Robertson, M., Colucci, W. S., & Dargie, H. J. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.06.002 · Cited by 25
After myocardial infarction carvedilol improves insulin resistance compared to metoprolol
Basat, O., Uçak, S., Seber, S., Öztekın, E., & Altuntaş, Y. (2006) · Clinical Research in Cardiology · doi:10.1007/s00392-006-0336-4 · Cited by 25
Management of Diabetes Mellitus in Older Adults: Are National Guidelines Appropriate?
Blaum, C. S. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50130.x · Cited by 25
Evolving Strategies for Use of Phytochemicals in Prevention and Long-Term Management of Cardiovascular Diseases (CVD)
Haines, D. D., Cowan, F. M., & Tósaki, Á. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116176 · Cited by 24
“This class of drugs is found to be particularly valuable in stabilizing cardiac arrhythmias to reduce the occurrence of secondary heart attacks following a first attack, and are also useful in the treatment of high blood pressure [85,86].”
Background
Usefulness of Beta Blockade in Contemporary Management of Patients With Stable Coronary Heart Disease
Winchester, D. E., & Pepine, C. J. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.08.026 · Cited by 24
Intraclass Differences Among Antihypertensive Drugs
Feldman, R. D., Hussain, Y., Kuyper, L. M., McAlister, F. A., Padwal, R. S., & Tobe, S. W. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124446 · Cited by 24
Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction
Zullo, A. R., Mogul, A., Corsi, K., Shah, N. R., Lee, S. J., Rudolph, J. L., Wu, W.-C. H., Dapaah‐Afriyie, R., Berard-Collins, C., & Steinman, M. A. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004942 · Cited by 24
“The mean (SD) age of the study cohort was 84 (8) years and the majority were female (n=3269; 68%) and white race (n=4014; 84%).”
Role of beta-blockers in patients with COPD: current perspective
Malerba, M., Montuschi, P., Radaeli, A., & Pirisi, M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.005 · Cited by 24
The Influence of Molecular Structure Modifications on Vibrational Properties of Some Beta Blockers: A Combined Raman and DFT Study
Farcaş, A.-A., Iacoviță, C., Vinţeler, E., Chiş, V., Stiufiuc, R. I., & Lucaciu, C. M. (2016) · Journal of Spectroscopy · doi:10.1155/2016/3137140 · Cited by 24
“The beta blockers are primarily used in the therapy of cardiovascular diseases [2].”
Background
Tackling inequalities: are secondary prevention therapies for reducing post-infarction mortality used without disparities?
Buja, A., Boemo, D. G., Furlan, P., Bertoncello, C., Casale, P., Baldovin, T., Marcolongo, A., & Baldo, V. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312462148 · Cited by 24
Chronic Ischaemic Heart Disease
Crea, F., Camici, P. G., Caterina, R. D., & Lanza, G. A. (2009) · doi:10.1093/med/9780199566990.003.017 · Cited by 24
Secondary Prevention Medication Use After Myocardial Infarction in U.S. Nursing Home Residents
Zullo, A. R., Sharmin, S., Lee, Y., Daiello, L. A., Shah, N. R., Boscardin, W. J., Dore, D. D., Lee, S. J., & Steinman, M. A. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15144 · Cited by 24
Genome‐Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β‐Blockers
Shahin, M. H., Conrado, D. J., González, D., Gong, Y., Lobmeyer, M. T., Beitelshees, A. L., Boerwinkle, E., Gums, J. G., Chapman, A. B., Turner, S. T., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.006463 · Cited by 24
Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents
Kim, Y. H., Her, A., Jeong, M. H., Kim, B., Lee, S., Hong, S., Shin, D., Kim, J., Ko, Y., Choi, D., et al. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6841-7 · Cited by 24
ST-Segment Elevation Myocardial Infarction
Antman, E. M., & Morrow, D. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00055-x · Cited by 25
Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension.
(2007) · PubMed Central · Cited by 24
Anti-ischemic therapy and stress testing: pathophysiologic, diagnostic and prognostic implications
Sicari, R. (2004) · Cardiovascular Ultrasound · doi:10.1186/1476-7120-2-14 · Cited by 24
What is the place of β-blockade in patients who have experienced a myocardial infarction with preserved left ventricular function? Evidence and (mis)interpretation
Freemantle, N., Urdahl, H., Eastaugh, J., & Hobbs, R. F. (2002) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2002.31586 · Cited by 24
Self-citation
β-Blockers for heart failure: why, which, when, and where
Cleland, J. G. F. (2003) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00173-6 · Cited by 24
Self-citation
The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?
Freestone, B., Beevers, D. G., & Lip, G. Y. H. (2004) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001694 · Cited by 24
Quo Vadis, Perioperative Beta Blockade? Are You “POISE'd” on the Brink?
London, M. J. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181684af6 · Cited by 23
Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark
Rasmussen, D. B., Bødtger, U. C. S., Lamberts, M., Nicolaisen, S. K., Sessa, M., Capuano, A., Torp-Pedersen, C. T., Gislason, G., Lange, P., & Jensen, M. T. (2019) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcy063 · Cited by 23
Determinants of Functional Improvement After Cardiac Rehabilitation in Acute Coronary Syndrome
Bianchi, S. P., Maloberti, A., Peretti, A., Garatti, L., Palazzini, M., Occhi, L., Bassi, I., Sioli, S., Biolcati, M., Giani, V., et al. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00473-7 · Cited by 23
Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction
Gheorghiade, M., & Fonarow, G. C. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.08.010 · Cited by 23
Effect of Core Laboratory and Multiple-Reader Interpretation of Angiographic Images on Follow-Up Outcomes of Coiled Cerebral Aneurysms: A Systematic Review and Meta-Analysis
Rezek, I., Mousan, G., Wang, Z., Murad, M. H., & Kallmes, D. F. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3398 · Cited by 23
Emerging clinical role of ranolazine in the management of angina
Wenger, N. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4468 · Cited by 23
Noninvasive, medical management for non–ST-elevation acute coronary syndromes
Chan, M. Y., Becker, R. C., Harrington, R. A., Peterson, E. D., Armstrong, P. W., White, H. D., Fox, K. A. A., Ohman, E. M., & Roe, M. T. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.11.014 · Cited by 23
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH PERSISTENT ST-SEGMENT ELEVATION
de Werf, F. V., Bax, J. J., Betriu, A., Blomström‐Lundqvist, C., Crea, F., Falk, V., Filippatos, G. S., Fox, K. A. A., Huber, K., Kastrati, A., et al. (2009) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2009-5-5-73-89 · Cited by 24
Treatment of stable ischaemic heart disease: the old and the new
Santucci, A., Riccini, C., & Cavallini, C. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa060 · Cited by 24
Modern Management of Acute Myocardial Infarction
Welch, T. D., Yang, E. H., Reeder, G. S., & Gersh, B. J. (2012) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.03.002 · Cited by 24
Antiarrhythmic effects of beta3-adrenergic receptor stimulation in a canine model of ventricular tachycardia
Zhou, S., Tan, A. Y., Paz, O., Ogawa, M., Chou, C.-C., Hayashi, H., Nihei, M., Fishbein, M. C., Chen, L. S., Lin, S., et al. (2007) · Heart Rhythm · doi:10.1016/j.hrthm.2007.10.014 · Cited by 23
Beta‐blockers in the treatment of cardiovascular disease
Cullington, D., Yassin, A., & Cleland, J. G. F. (2008) · Prescriber · doi:10.1002/psb.253 · Cited by 23
Self-citation
Cardiovascular Effects of -Agonists in Patients With Asthma and COPD*
Salpeter, S. R., Ormiston, T. M., & Salpeter, E. E. (2006) · Cited by 23
A population-based analysis of the class effect of β-blockers after myocardial infarction
Rinfret, S., Abrahamowicz, M., Tu, J. V., Humphries, K. H., Eisenberg, M. J., Richard, H., Austin, P. C., & Pilote, L. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.11.008 · Cited by 23
Review of Current Management of Myocardial Infarction
Saha, T., & Soliman-Aboumarie, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176241 · Cited by 30
“Beta-blockers should be initiated within 24 h, provided there are no contraindications such as heart failure, hypotension, atrioventricular block, or reactive airway disease [44].”
Traditional Heart Failure Medications and Sudden Cardiac Death Prevention
Chekakie, M. O. A. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413491496 · Cited by 22
Anticoagulation after Anterior Myocardial Infarction and the Risk of Stroke
Udell, J. A., Wang, J. T., Gladstone, D. J., & Tu, J. V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012150 · Cited by 22
Revisiting the Quality Chasm
Brilli, R. J., Allen, S., & Davis, J. T. (2014) · PEDIATRICS · doi:10.1542/peds.2013-3090 · Cited by 22
Pre-hospital ECG for acute coronary syndrome in urban India: A cost-effectiveness analysis
Schulman‐Marcus, J., Prabhakaran, D., & Gaziano, T. A. (2010) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-10-13 · Cited by 24
β-Blockers in coronary artery disease management.
Boudonas, G. (2010) · PubMed Central · Cited by 22
Ivabradine: from molecular basis to clinical effectiveness
Riccioni, G. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0014-9 · Cited by 22
Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death
Boriani, G., Valzania, C., Diemberger, I., Biffi, M., Martignani, C., Bertini, M., Ziacchi, M., Domenichini, G., Saporito, D., Rapezzi, C., et al. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.5.605 · Cited by 22
“Several meta-analyses [19-24] have reported that β-blocker therapy is associated with clinically meaningful reductions in mortality in patients with congestive heart failure.”
Background
OFF-LABEL PRESCRIBING. POSSIBLE CAUSES, TYPES AND CONSEQUENCES. LEGAL REGULATION IN THE RUSSIAN FEDERATION
Martsevich, S. Y., Рубенович, Н. А., & Алексеевна, К. Н. (2017) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2017-13-5-667-674 · Cited by 22
Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization
Sim, H. W., Zheng, H., Richards, M., Chen, R. W., Sahlén, A., Yeo, K. K., Tan, J. W., Chua, T. S. J., Tan, H. C., Yeo, T. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72232-y · Cited by 23
Documento de Consenso de Expertos sobre bloqueadores de los receptores ß-adrenérgicos
Beta, G. D. T. S. B., & de Cardiología, D. L. S. E. (2005) · Revista Española de Cardiología · doi:10.1157/13070510 · Cited by 22
Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice
Asfaha, S., & Padwal, R. S. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0063-7 · Cited by 22
Efecto de la asociación de bloqueadores beta e inhibidores de la enzima de conversión en la supervivencia al año tras un infarto agudo de miocardio. Resultados del registro PRIAMHO II
Arós, F., de Loma-Osorio, A. F., Vila, J., López‐Bescós, L., Cuñat, J., Rodríguez, E., José, J. M. S., Heras, M., & Marrugat, J. (2006) · Revista Española de Cardiología · doi:10.1157/13087059 · Cited by 23
Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome
Douglas, K., Pace, A. V., Treharne, G. J., Saratzis, A. N., Nightingale, P., Erb, N., Banks, M., & Kitas, G. D. (2006) · PubMed Central · Cited by 22
Expanding Indications for Defibrillators after Myocardial Infarction: Risk Stratification and Cost Effectiveness
Essebag, V., & Eisenberg, M. J. (2003) · Cardiac Electrophysiology Review · doi:10.1023/a:1023639006565 · Cited by 22
What is Right and What is Wrong About Evidence‐Based Medicine?
Julian, D. G. (2003) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.14.s9.18.x · Cited by 22
What is the optimal medical management of ischemic heart failure?
Cleland, J. G. F., Alamgir, F. M., Nikitin, N. P., Clark, A. L., & Norell, M. S. (2001) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2001.20670 · Cited by 22
Self-citation
Routine Beta-Blockers in Secondary Prevention — On Injured Reserve
Steg, P. G. (2024) · New England Journal of Medicine · doi:10.1056/nejme2402731 · Cited by 22
Determinants of cardiovascular mortality in a cohort of primary care patients with chronic ischemic heart disease. BARBANZA Ischemic Heart Disease (BARIHD) study
Vidal-Pérez, R., Otero-Raviña, F., Franco, M., Garcia, J. M. R., Stolle, R. L., Álvarez, R. E., Díaz, C. I., Lopez, E., Lopez, M. J., & González‐Juanatey, J. R. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.01.014 · Cited by 21
Investigating the predictive value of microRNA21 as a biomarker in induced myocardial infarction animal model
Hosseini, M., Sahebi, R., Aghasizadeh, M., Yazdi, D. F., Salaribaghoonabad, R., Godsi, A., Soflaei, S. S., Mousavitaherabad, S. P., Ahmadihoseini, A., Bajgiran, M. M., et al. (2022) · Gene Reports · doi:10.1016/j.genrep.2022.101578 · Cited by 21
Optical control of the β2-adrenergic receptor with opto-prop-2: A cis-active azobenzene analog of propranolol
Bosma, R., Dijon, N. C., Zheng, Y., Schihada, H., Hauwert, N. J., Shi, S., Arimont, M., Riemens, R., Custers, H., van de Stolpe, A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104882 · Cited by 21
Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation
Sikirić, P., Udovičić, M., Barišić, I., Balenović, D., Živanović-Posilović, G., Strinić, D., Uzun, S., Sikirić, S., Krezić, I., Žižek, H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112696 · Cited by 21
“Likewise, the wide cytoprotection agenda might also be distinctive from the focused background of the angiotensin-converting-enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers [45–47], or beta-blockers [48].”
Background
Heart Rate-Lowering Efficacy and Respiratory Safety of Ivabradine in Patients with Obstructive Airway Disease
Majewski, S., Słomka, S., Zielińska-Wyderkiewicz, E., Ciebiada, M., & Górski, P. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11597400-000000000-00000 · Cited by 21
Preparative enantioseparation of β-blocker drugs by counter-current chromatography using dialkyl l-tartrate as chiral selector based on borate coordination complex
Tong, S., Zheng, Y., Yan, J., Guan, Y., Wu, C., & Lei, W. (2012) · Journal of Chromatography A · doi:10.1016/j.chroma.2012.09.023 · Cited by 21
Why Is Modern Medicine Stuck in a Rut?
Mittra, I. (2009) · Perspectives in biology and medicine · doi:10.1353/pbm.0.0131 · Cited by 22
Use of a coronary heart disease simulation model to evaluate the costs and effectiveness of drugs for the prevention of heart disease
Cooper, K., Davies, R., Raftery, J. P., & Roderick, P. J. (2007) · Journal of the Operational Research Society · doi:10.1057/palgrave.jors.2602468 · Cited by 21
The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation
Ye, W., Brändle, M., Brown, M. B., & Herman, W. H. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0304 · Cited by 21
Approaches for the Management of Resistant Hypertension in 2020
Aronow, W. S. (2020) · Current Hypertension Reports · doi:10.1007/s11906-019-1013-0 · Cited by 21
MI with Non-obstructive Coronary Artery Presenting with STEMI: A Review of Incidence, Aetiology, Assessment and Treatment
Gue, Y. X., Kanji, R., Gati, S., & Gorog, D. A. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.13 · Cited by 22
Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: A retrospective analysis
van der Elst, M. E., Bouvy, M. L., Blaey, C. J. D., & de Boer, A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.11.003 · Cited by 21
Nonantithrombotic Medical Options in Acute Coronary Syndromes
Soukoulis, V., Boden, W. E., Smith, S. C., & O’Gara, P. T. (2014) · Circulation Research · doi:10.1161/circresaha.114.302804 · Cited by 24
Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with β-blockers
Marie, P., Mercennier, C., Danchin, N., Djaballah, K., Grentzinger, A., Zannad, F. M., Olivier, P., Djaballah, W., Karcher, G., Virion, J. M., et al. (2003) · Journal of Nuclear Cardiology · doi:10.1016/s1071-3581(03)00429-x · Cited by 21
Am I Getting the Influenza Shot Too?: Influenza Vaccination as Post–Myocardial Infarction Care for the Prevention of Cardiovascular Events and Death
Michos, E. D., & Udell, J. A. (2021) · Circulation · doi:10.1161/circulationaha.121.057534 · Cited by 21
Publication trends and knowledge maps of global translational medicine research
Ma, F., Lyu, P., Yao, Q., Yao, L., & Zhang, S. (2013) · Scientometrics · doi:10.1007/s11192-013-1003-y · Cited by 20
Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome
Bezin, J., Groenwold, R. H. H., Ali, M. S., Lassalle, R., Robinson, P., de Boer, A., Moore, N. D., Klungel, O. H., & Pariente, A. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4171 · Cited by 20
The Impact of Hemodynamic Reflex Compensation Following Myocardial Infarction on Subsequent Ventricular Remodeling
Witzenburg, C. M., & Holmes, J. W. (2019) · Journal of Biomechanical Engineering · doi:10.1115/1.4043867 · Cited by 20
β-Blocker Use and Cardiovascular Outcomes in Hemodialysis: A Systematic Review
Tella, A., Vang, W., Ikeri, E. C., Taylor, O., Zhang, A., Mazanec, M., Raju, S. I., & Ishani, A. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100460 · Cited by 20
“In the general population, β-blockers have been demonstrated to improve outcomes among patients with a history of cardiovascular disease.(1)”
Background
Angina in 2022: Current Perspectives
Manfredi, R., Verdoia, M., Compagnucci, P., Barbarossa, A., Stronati, G., Casella, M., Russo, A. D., Guerra, F., & Ciliberti, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236891 · Cited by 22
Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it
Joo, S. (2023) · Acute and Critical Care · doi:10.4266/acc.2023.00955 · Cited by 21
Anti-hypertensive medications and erectile dysfunction: focus on β-blockers
Corona, G., Vena, W., Pizzocaro, A., Salvio, G., Sparano, C., Sforza, A., & Maggi, M. (2024) · Endocrine · doi:10.1007/s12020-024-04020-x · Cited by 23
Age, Dementia and Care Patterns after Admission for Acute Coronary Syndrome
Lin, C.-F., Wu, F. L., Lin, S., Bai, C. H., Chan, D., Gau, C., Hsiao, F., & Shen, L. (2012) · Drugs & Aging · doi:10.1007/s40266-012-0011-6 · Cited by 20
β-Blocker Therapy in the Era of Primary Percutaneous Intervention for ST Elevation Myocardial Infarction
Lee, Y.-H., Park, J., Tahk, S., Hwang, G., Yoon, M., Choi, S., Choi, B., Lim, H., Yang, H., Seo, K., et al. (2015) · Cardiology · doi:10.1159/000431077 · Cited by 20
Analysing falls in coronary heart disease mortality in the West Bank between 1998 and 2009
Abu-Rmeileh, N. M. E., Shoaibi, A., O’Flaherty, M., Capewell, S., & Husseini, A. S. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001061 · Cited by 20
Review of Top 10 Prescribed Drugs and Their Interaction with Dental Treatment
Weinstock, R. J., & Johnson, M. P. (2016) · Dental Clinics of North America · doi:10.1016/j.cden.2015.11.005 · Cited by 20
Pharmacological treatments of cardiovascular diseases: Evidence from real-life studies
Salvo, F., Bezin, J., Bosco‐Lévy, P., Létinier, L., Blin, P., Pariente, A., & Moore, N. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.006 · Cited by 24
Developed electrochemical sensors for the determination of beta-blockers: A comprehensive review
Sarvestani, M. R. J., Madrakian, T., & Afkhami, A. (2021) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2021.115666 · Cited by 20
[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish adaptation].
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · PubMed · Cited by 20
Effect of drug combinations on admission for recurrent myocardial infarction
van der Elst, M. E., Bouvy, M. L., Blaey, C. J. D., & de Boer, A. (2007) · Heart · doi:10.1136/hrt.2006.098053 · Cited by 20
Benefit of Vasodilating β‐Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter Cohort Study
Chung, J., Han, J., Kim, Y. J., Kim, C. J., Ahn, Y., Cho, M., Chae, S. C., Chae, I., Chae, J. K., Seong, I. W., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007063 · Cited by 20
Ischemic heart disease in type 2 diabetes
Otel, I., Ledru, F., & Danchin, N. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00216-6 · Cited by 20
Simple, rapid, and sensitive determination of beta‐blockers in environmental water using dispersive liquid–liquid microextraction followed by liquid chromatography with fluorescence detection
Vázquez, M. D. M. P., Vázquez, P. P., Galera, M. M., & Sánchez, L. M. (2012) · Journal of Separation Science · doi:10.1002/jssc.201200222 · Cited by 20
Role of beta blockers following percutaneous coronary intervention for acute coronary syndrome
Peck, K. Y., Andrianopoulos, N., Dinh, D. T., Roberts, L., Duffy, S. J., Sebastian, M., Clark, D., Brennan, A., Oqueli, E., Ajani, A. E., et al. (2020) · Heart · doi:10.1136/heartjnl-2020-316605 · Cited by 19
Occurrence, removal, and prioritization of organic micropollutants in four full-scale wastewater treatment plants in Korea.
Choi, S., Lee, W., Son, H., Lee, W., Choi, Y., Yoom, H., Seo, C., Lee, H., Lee, Y.-J., Lim, S.-J., et al. (2024) · Chemosphere · doi:10.1016/j.chemosphere.2024.142460 · Cited by 14
Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida
y otras, C. G. D. T. C. D. L. S. E. D. C., & Clínica, S. S. P. D. L. E. C. E. L. P. (2008) · Revista Española de Cardiología · doi:10.1157/13114961 · Cited by 19

Authors: Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J.
Affiliations: University of York (GB)
University of Hull (GB)
Corresponding author: Freemantle, N.
ORCID: Freemantle, N.
Cleland, J.
Mason, J.
Venue: BMJ
Publisher: BMJ
Published: 1999-06-26
Volume: 318
Issue: 7200
Pages: 1730-1737
ISSN: 0007-1447 (ISSN-L)
0959-8138
1468-5833
DOI: 10.1136/bmj.318.7200.1730
PMC: PMC31101
OpenAlex: W2070568974
Cited by: 1,509
References: 34
Citations by year: 2026: 27 · 2025: 43 · 2024: 38 · 2023: 30 · 2022: 42 · 2021: 36 · 2020: 49 · 2019: 47 · 2018: 53 · 2017: 57 · 2016: 58 · 2015: 48 · 2014: 67 · 2013: 74 · 2012: 83
FWCI: 7.55
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: BMJ (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
Keywords: beta-blockers, myocardial infarction, secondary prevention, all-cause mortality, reinfarction, cardioselectivity, intrinsic sympathomimetic activity, propranolol, timolol, metoprolol, number needed to treat, predictors of treatment response
MeSH terms: Adrenergic beta-Antagonists, Humans, Myocardial Infarction, Regression Analysis, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

beta Blockade after myocardial infarction: systematic review and meta regression analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks